Plain-English translation of NCT07114874 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a long-term safety study of a medication called being developed to treat schizophrenia. The study will follow adults with schizophrenia who take this medication once daily by mouth for up to 36 months. Researchers want to understand how well this treatment works and what side effects people might experience over time.
While this medication has already been tested in earlier studies, researchers need to know whether it remains safe and well-tolerated when people take it for extended periods. This longer-term information is essential before the medication can be approved and made available to patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take the medication by mouth once each day for up to three years. You will have regular visits with study doctors who will monitor your health, check for any side effects, and make sure the treatment is working well for you. The study involves 600 participants across multiple locations worldwide, so you'll be part of a large research effort to understand this treatment's long-term safety.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States